Fig. 4From: Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trialProgression-free survival of the DP group and the PF groupDP: docetaxel plus cisplatin; PF: cisplatin plus 5-FU; PFS: progression-free survivalBack to article page